This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Incyte Corp. (INCY) slid 1.19% to $99.13 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.11% to 49,760.56 and the S&amp;P 500 Index falling 0.16% to 7,400.96.
The stock's fall snapped a two-day winning streak.
Incyte Corp. closed 11.72% short of its 52-week high of $112.29, which the company achieved on January 7th.
The stock underperformed when compared to some of its competitors Tuesday, as Alnylam Pharmaceuticals Inc. (ALNY) rose 2.52% to $292.03, Bio-Techne Corp. (TECH) remained unchanged, and BioMarin Pharmaceutical Inc. (BMRN) rose 0.57% to $52.88.
Trading volume (1.6 M) eclipsed its 50-day average volume of 1.5 M.
Data source: Dow Jones Market Data, FactSet. Data compiled May 12, 2026.
This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
05-12-26 1707ET

INCY

ARKG

Incyte Corp. (INCY) shares fell 1.19% to $99.13 on Tuesday, ending a two-day winning streak, while the Dow Jones rose 0.11% and the S&P 500 fell 0.16%. The stock is 11.72% below its 52-week high of $112.29. In comparison, competitors like Alnylam Pharmaceuticals (ALNY) rose 2.52%, while Bio-Techne (TECH) remained unchanged and BioMarin Pharmaceutical (BMRN) increased by 0.57%. Trading volume was 1.6 million, surpassing the 50-day average of 1.5 million.

MarketWatch Automated

Incyte

Ark Genomic Revolution ETF

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

VG Health

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

ALPS Medical Breakthrough

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Dow Jones Industrial Average

S&P 500

Alnylam Pharma

Bio-Techne

BioMarin Pharma

Incyte Corp. Stock Underperforms Tuesday When Compared To Competitors